Oorja Bio

Oorja Bio, Inc. is a clinical-stage biopharmaceutical company developing groundbreaking therapies for idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary diseases. The company's approach targets the underlying pathophysiology of disease — promoting cellular repair, reversing fibrotic tissue damage, and remodeling the lung architecture — going beyond symptom management to establish a new standard of care. Its lead drug candidate, ORJ-001, is a first-in-class peptide therapeutic for subcutaneous administration designed to restore the function of alveolar epithelial type 2 (AEC2) cells, a key driver of pulmonary fibrosis pathogenesis. ORJ-001 acts as an agonist of β1 integrin and has demonstrated reversal of established fibrosis in preclinical models. The company received FDA IND clearance and initiated a Phase 2 clinical trial in 2026. Oorja Bio was founded by a team of biotechnology leaders with a proven track record at Acceleron Pharma and Merck, and is based at the Texas Medical Center in Houston. It launched from stealth in May 2026 with $30 million in Series A financing from founding investor Westlake BioPartners.